Selecta Biosciences, Inc. Gross Margin

Gross Margin of SELB for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Margin growth rates and interactive chart. Gross profit margin shows the percentage of revenue that exceeds a company's costs of goods sold. It illustrates how well a company is generating revenue from the costs involved in producing their products and services. The higher the margin, the more effective the company's management is in generating revenue for each dollar of cost. Gross profit margin is calculated by subtracting the cost of goods sold from total revenue for the period and dividing that number by revenue. If a company has $200 million in revenue and $80 million in cost of goods sold, the gross margin is 60%.


Highlights and Quick Summary

  • Gross Margin for the quarter ending March 30, 2021 was 100.0% (a 0.0% decrease compared to previous quarter)
  • Year-over-year quarterly Gross Margin increased by Infinity%
  • Annual Gross Margin for 2020 was 100.0% (a 0.0% decrease from previous year)
  • Annual Gross Margin for 2019 was 100.0% (a 0.0% decrease from previous year)
  • Annual Gross Margin for 2018 was 100.0% (a 0.0% decrease from previous year)
  • Twelve month Gross Margin ending March 30, 2021 was 79.55% (a 18.34% increase compared to previous quarter)
  • Twelve month trailing Gross Margin increased by Infinity% year-over-year
Trailing Gross Margin for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
79.55% 67.22% 91.34% 0.0%
Visit stockrow.com/SELB for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Margin of Selecta Biosciences, Inc.

Most recent Gross Marginof SELB including historical data for past 10 years.

Interactive Chart of Gross Margin of Selecta Biosciences, Inc.

Selecta Biosciences, Inc. Gross Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 100.0%
2020 100.0% 100.0% 0.0% 0.0% 100.0%
2019 100.0% 100.0% 100.0% 100.0%
2018 100.0%
2017 100.0% 100.0% 100.0% 100.0% 100.0%
2016 100.0% 100.0% 100.0% 100.0% 100.0%
2015 100.0% 100.0% 100.0%
2014 100.0%

Business Profile of Selecta Biosciences, Inc.

Sector: Healthcare
Industry: Biotechnology
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.